Shaun Hawkins is the founder of the ProSyte Companies, a diversified holding entity investing in businesses and real estate in the United States Midwest, as well as communications and infrastructure entities in West Africa.
From 2012 until his departure in 2015, Mr. Hawkins was Vice President of New Ventures and Private Equity Investing at Eli Lilly. In this capacity, Mr. Hawkins was responsible for Eli Lilly’s venture capital, private equity and venture formation activities, managing over $1.5 billion. Mr. Hawkins joined Eli Lilly in 2001 and held various roles in sales and corporate business development at the company. In 2010, Mr. Hawkins was promoted to Chief Diversity Officer to lead the development and implementation of Eli Lilly’s global diversity and inclusion strategy.
Mr. Hawkins graduated magna cum laude with a bachelor’s degree in business from the University of Tennessee in 1995, and earned a master’s degree in business administration from the Kellogg School of Management at Northwestern University in 2000.
Mr. Hawkins currently serves on the ImmuneWorks, Inc. board of directors as well as the advisory council of the Indianapolis Recorder Newspaper. He was previously the board chair for Audion Therapeutics, B.V. (Netherlands) and Muroplex Therapeutics, Inc. (U.S.) as well as a board member of the Accelerator Corporation (U.S.) and Zymeworks, Inc (Canada). He was also a member of the limited partner advisory committees of BioCrossroads’ Indiana Enterprise Fund (U.S.), Epidarex Capital (U.K.), the Indiana Future Fund/INext Fund (U.S.) and TVM Capital (Canada and Germany).